Silence Therapeutics plc
Nasdaq SLN · London, United Kingdom
Works in Hematology · Metabolic & endocrine · Oncology
Silence Therapeutics plc is a clinical trial sponsor based in London, United Kingdom, listed as Nasdaq SLN. It has 1 active clinical trial with 69 planned participants, in Hematology, Metabolic & endocrine and Oncology. Since 2021 it has completed 4 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq SLN
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Silence Therapeutics plc
Silence Therapeutics plc is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 69 planned participants, in Hematology, Metabolic & endocrine, Oncology. Since 2021 it has completed 4 trials and stopped 0 early.
Silence Therapeutics plc is based in London, United Kingdom and is listed as Nasdaq SLN. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Silence Therapeutics plc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2025-12-19.
Approve Suite is not affiliated with Silence Therapeutics plc.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.